Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity

Br J Haematol. 2018 May;181(3):413-417. doi: 10.1111/bjh.14624. Epub 2017 Apr 27.
No abstract available

Keywords: ADCC; CD20; IgA antibody; antibody therapy; myeloid effector cells.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibody-Dependent Cell Cytotoxicity / drug effects*
  • Antigens, CD20 / immunology*
  • Antineoplastic Agents, Immunological / immunology
  • Antineoplastic Agents, Immunological / pharmacology*
  • CHO Cells
  • Complement System Proteins / immunology*
  • Cricetulus
  • Humans
  • Immunoglobulin A / immunology
  • Immunoglobulin A / pharmacology*
  • Leukemia, Prolymphocytic, B-Cell / drug therapy
  • Leukemia, Prolymphocytic, B-Cell / immunology*
  • Leukemia, Prolymphocytic, B-Cell / pathology
  • Myeloid Cells / immunology*
  • Myeloid Cells / pathology

Substances

  • Antigens, CD20
  • Antineoplastic Agents, Immunological
  • Immunoglobulin A
  • Complement System Proteins